Strategic Industry Investment Driving the Jet Injector Market From $190.3 Million in 2025 to $346.7 Million by 2035

Jet injector market was valued at $190.3 million in 2025 and is expected to reach $346.7 million by 2035, expanding at a CAGR of 6.2% over the 2026–2035 forecast period. Rising industry investment and expanding clinical validation are emerging as a central driver for the jet injector market. Pharmaceutical companies and device developers are scaling needle-free platforms to improve vaccine delivery, enhance drug performance, and address injection hesitancy at the point of care. As these systems demonstrate faster workflows, simplified training, and compatibility with existing clinical practices, jet injectors are moving from niche use cases into mainstream immunization and therapeutic programs. This shift is strengthening adoption across vaccine delivery, insulin administration, and other applications, while reinforcing demand from pharmaceutical companies, hospitals, and clinical centres seeking safer, more efficient delivery alternatives.

Browse the full report description of “Jet Injector Market Size, Share & Trends Analysis Report by Product (Prefilled Needle-Free Injectors, and Fillable Needle-Free Injectors), By Application (Insulin Delivery, Respiratory Delivery, Vaccine Delivery, and Others), by Technology (Jet Based, Spring Based, Laser Power Based and Vibration Based), By End-User (Pharmaceutical Companies, Hospital & Clinical Centres, and Others) Forecast Period, (2026-2035)” of https://www.omrglobal.com/industry-reports/jet-injector-market

Recent developments highlight the scale and momentum behind this driver. PharmaJet reports delivering tens of millions of needle-free injections globally and maintaining over 80 pharmaceutical partnerships, reflecting strong industry confidence and deployment at scale. Its Stratis and Tropis devices are WHO-prequalified and used worldwide for vaccine delivery, including polio eradication programs. The Tropis ID Needle-free Injection System delivers a precise 0.1 ml intradermal dose without needles and achieves a 25% faster workflow than traditional Mantoux injections, administering doses in about one-tenth of a second. Preference data shows 97.6% of vaccinators and 99.6% of caregivers favor Tropis over needle-based methods. The system requires only about 20 minutes of training, follows a familiar four-step workflow, and supports a wide range of injectables. In October 2023, Daicel Corporation made a strategic investment in PharmaJet and established Daicel Medical Ltd., further reinforcing its long-term commitment to needle-free delivery. PharmaJet is currently supporting 26 ongoing clinical studies across infectious diseases and immuno-oncology, including COVID-19, HPV, influenza, melanoma, and leukemia.

Recent Product Expansion and Program Deployments Strengthening the Jet Injector Market

• In October 2025, PharmaJet expanded its needle-free injection technology by developing proprietary, needle-free self-injector pens for subcutaneous use, targeting chronic disease and metabolic peptide markets.

• In June 2024, PharmaJet’s Tropis Intradermal Needle-free System will be used in a two-round house-to-house polio vaccination campaign in Banadir, Somalia. Targeting over 170,000 children aged 4-59 months, the campaign aims for 95% coverage to close the immunity gap against type-2 poliovirus.

• In December 2023, Advance Medical Life Co. Ltd., based in Bangkok, became the exclusive distributor in Thailand for NuGen Medical Devices' needle-free InsuJet device, designed to enhance subcutaneous therapeutic delivery for diabetics globally.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • Product
  • Application
  • Technology
  • End-User
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape – Antares Pharma, Inc., Crossject SA, Daicel Corp., InsuJet, PharmaJet, Inc., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Jet Injector Market Report Segment

By Product

• Prefilled Needle-Free Injectors
• Fillable Needle-Free Injectors

By Application

• Insulin Delivery
• Respiratory Delivery
• Vaccine Delivery
• Others

By Technology

• Jet Based
• Spring Based
• Laser Power Based
• Vibration Based

By End-User

• Pharmaceutical Companies
• Hospital & Clinical Centres
• Others

Global Jet Injector Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

 To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/jet-injector-market